*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Jiangsu Hengrui Pharmaceuticals Co., Ltd.
# 江蘇恒瑞醫藥股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1276)**

## OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
**Jiangsu Hengrui Pharmaceuticals Co., Ltd.**
**江蘇恒瑞醫藥股份有限公司**
**Mr. Sun Piaoyang**
*Chairman*

Shanghai, PRC
October 27, 2026

*As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.*

Stock code: 600276 Stock abbreviation: Hengrui Pharma No.: Lin 2026-161

# Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the "Company") received a notice from the National Medical Products Administration (the "NMPA") approving an additional indication for the Company's Class 1 innovative drug, Remimazolam Tosilate for Injection, for sedation during mechanical ventilation in intensive care. The relevant information is hereby announced as follows:

## I. Basic Information of the Drug

Drug Name: Remimazolam Tosilate for Injection

Dosage Form: Injection

Strength: 36 mg (calculated based on $C_{21}H_{19}BrN_4O_2$)

Registration Category: Chemical Drug Class 2.4

Acceptance No.: CXHS2500146

Prescription Drug/Over-the-Counter Drug: Prescription drug

Approved Indication: For sedation during mechanical ventilation in intensive care.

## II. Previously Approved Indications of the Drug

The Company's remimazolam tosilate for injection has been approved for marketing in China for multiple indications, namely: sedation and anesthesia for non-intubated surgeries/procedures, as well as induction and maintenance of general

anesthesia.

**III. Other Information of the Drug**

Sedation management in critically ill patients receiving mechanical ventilation is a key component of ICU care. Standardized sedation can alleviate stress responses, improve patient-ventilator synchrony, preserve organ reserve, shorten the duration of mechanical ventilation and ICU stay, reduce the risk of delirium, and improve patient prognosis. However, traditional sedatives carry risks of circulatory and respiratory depression. Long-term infusion may lead to drug accumulation and delayed awakening. Elderly patients and those with hepatic or renal insufficiency have poor tolerability and are more likely to experience prolonged mechanical ventilation and longer ICU stays, which may affect ventilator weaning and long-term prognosis[1,2]. Therefore, significant unmet clinical needs remain in terms of both efficacy and safety in current ICU sedation therapy.

Remimazolam tosilate is a benzodiazepine and a short-acting GABAa receptor agonist. It produces sedative and anesthetic effects by binding to GABAa receptors and inhibiting neuronal activity. Its advantages include rapid onset of action, short recovery time, and minimal effects on the respiratory and cardiovascular systems. Remimazolam besylate, developed by PAION AG in Germany, was approved for marketing in Japan in January 2020, in the United States in October 2020, and in China in July 2020. According to available data, the global sales of remimazolam besylate were approximately USD 59.22 million in 2024. As of now, the cumulative R&D investment in projects related to remimazolam tosilate for injection amounts to approximately RMB 222.5 million (unaudited).

**IV. Risk Warning**

The Company places great importance on drug R&D and strictly controls quality and safety throughout drug R&D, manufacturing, and sales processes. However, upon obtaining approval, the drug's production and sales may be susceptible to various uncertainties. Investors are kindly advised to be prudent in investment decisions, paying attention to the risks involved.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

October 27, 2026

[1] Chinese Society of Critical Care Medicine, Chinese Medical Association. Guidelines for Analgesia and Sedation Treatment in Intensive Care Unit of Chinese Adults [J]. Chinese Critical Care Medicine, 2018, 30 (6): 497–514.

[2] Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines by the Society of Critical Care Medicine for the management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU [J]. Crit Care Med, 2018,46 (9):1532 1587.